Holen Sie sich die Stockscreener-App
0.7248
0.61%
0.0044
Handel nachbörslich:
.72
-0.0048
-0.66%
Schlusskurs vom Vortag:
$0.7204
Offen:
$0.7499
24-Stunden-Volumen:
1.51M
Relative Volume:
1.27
Marktkapitalisierung:
$13.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.60M
KGV:
-0.8144
EPS:
-0.89
Netto-Cashflow:
$-23.48M
1W Leistung:
+15.05%
1M Leistung:
-64.12%
6M Leistung:
-81.08%
1J Leistung:
-91.67%
1-Tages-Spanne:
$0.6882
$0.75
1-Wochen-Bereich:
$0.6298
$0.75
52-Wochen-Spanne:
$0.61
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Firmenname
Briacell Therapeutics Corp
Sektor
Branche
Telefon
(604) 921-1810
Adresse
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Vergleichen Sie BCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.7248 | 12.10M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
BriaCell Joins MSK’s 2025 Therapeutics Accelerator Program - TipRanks
BriaCell's Strategic Alliance with MSK and the Acceleration of Bria-OTS+ as a Game-Changer in Cancer Immunotherapy - AInvest
BriaCell Selected for MSK's 2025 Therapeutics Accelerator Progra - GuruFocus
BriaCell joins Memorial Sloan Kettering’s Therapeutics Accelerator program By Investing.com - Investing.com South Africa
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer - GlobeNewswire
Memorial Sloan Kettering Selects BriaCell's Novel Cancer Immunotherapy for 2025 Development Program - Stock Titan
Will BriaCell Therapeutics Corp. Equity Warrant Sustain Its Chart BreakoutGrowth Based Stock Signal Screener Updated - 선데이타임즈
BriaCell Shares Slide 22% After Announcing Dilutive Public Offering - MSN
BriaCell Therapeutics To Carry Out 1-for-10 Reverse Stock Split On August 25th, 2025 - 富途牛牛
BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance - The Globe and Mail
BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan
BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire
My Honest Opinion of Energy Transfer Stock - The Globe and Mail
Simon Property Reports Strong Q2 2025 Financial Results - The Globe and Mail
What institutional investors are buying BriaCell Therapeutics Corp. Equity Warrant stockUnlock powerful stock screening techniques - Jammu Links News
How does BriaCell Therapeutics Corp. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant generate profit in a changing economySuperior risk-adjusted returns - Jammu Links News
(BCT) Technical Pivots with Risk Controls (BCT:CA) - news.stocktradersdaily.com
What institutional investors are buying BriaCell Therapeutics Corp. stockDiscover the next big stock winners - Jammu Links News
What makes BriaCell Therapeutics Corp. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News
How volatile is BriaCell Therapeutics Corp. Equity Warrant stock compared to the marketMassive portfolio appreciation - Jammu Links News
BriaCell Therapeutics Corp. Equity Warrant Stock Analysis and ForecastGet daily updates on promising stocks - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant compare to its industry peersHigh-octane gains - Jammu Links News
What makes BriaCell Therapeutics Corp. Equity Warrant stock price move sharplyUnlock powerful market insights for success - Jammu Links News
What drives BriaCell Therapeutics Corp. Equity Warrant stock priceMaximize returns with data-driven strategies - Jammu Links News
What is the dividend policy of BriaCell Therapeutics Corp. Equity Warrant stockMaximize gains with expert analysis - Jammu Links News
Published on: 2025-08-03 12:02:14 - Jammu Links News
What is the risk reward ratio of investing in BriaCell Therapeutics Corp. Equity Warrant stockAchieve consistent double-digit returns - Jammu Links News
Should I hold or sell BriaCell Therapeutics Corp. Equity Warrant stock in 2025Tremendous return rates - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. Equity Warrant stock higher in 2025Invest smarter with comprehensive market analysis - Jammu Links News
How does BriaCell Therapeutics Corp. generate profit in a changing economyProven strategies for superior portfolio growth - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. stock higher in 2025Sky-high return potential - Jammu Links News
Is BriaCell Therapeutics Corp. Equity Warrant stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Is it the right time to buy BriaCell Therapeutics Corp. Equity Warrant stockDouble-digit growth - Jammu Links News
Off-market insider buying at Atico Mining (ATY) - The Globe and Mail
BriaCell Therapeutics Corp. Recovery Hinges on Volume BreakoutWeekly Setup With 3x Return Potential Published - metal.it
Is BriaCell Therapeutics Corp. a growth stock or a value stockPre Market Review For Consistent Profits - Jammu Links News
BriaCell Expands Phase 3 Breast Cancer Study with UCLA Health Partnership - TipRanks
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - GlobeNewswire
UCLA Health joins BriaCell’s phase 3 breast cancer study By Investing.com - Investing.com Nigeria
UCLA Health joins BriaCell’s phase 3 breast cancer study - Investing.com
FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan
Foraco International reports Q2 2025 - The Globe and Mail
WALSH PURE SPREADER -Pure Hedge Division - The Globe and Mail
BriaCell granted New Zealand patent for cancer immunotherapy method By Investing.com - Investing.com South Africa
BriaCell granted New Zealand patent for cancer immunotherapy method - Investing.com
BriaCell Awarded New Zealand Patent for its Whole Cell Technology - GlobeNewswire
Finanzdaten der Briacell Therapeutics Corp-Aktie (BCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):